Efaroksan
Izgled
(IUPAC) ime | |||
---|---|---|---|
2-(2-etil-2,3-dihudro-1-benzofuran-2-il)-4,5-dihidro-1H-imidazol | |||
Klinički podaci | |||
Identifikatori | |||
CAS broj | 89197-32-0 | ||
ATC kod | nije dodeljen | ||
PubChem[1][2] | 72016 | ||
ChemSpider[3] | 65015 | ||
UNII | G00490L21H | ||
ChEMBL[4] | CHEMBL57895 | ||
Hemijski podaci | |||
Formula | C13H16N2O | ||
Mol. masa | 216,28 g/mol | ||
SMILES | eMolekuli & PubHem | ||
| |||
Farmakoinformacioni podaci | |||
Trudnoća | ? | ||
Pravni status | nekontrolisan | ||
Način primene | Oralno |
Efaroksan je antagonist α2-adrenergičkog receptora .[5]
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.
- ↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594.
- ↑ Chopin P, Colpaert FC, Marien M (February 1999). „Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway”. J. Pharmacol. Exp. Ther. 288 (2): 798–804. PMID 9918591.